Pulmonary aspergillosis in a Crohn's disease patient receiving adalimumab and steroid therapy

Gastroenterol Hepatol. 2019 Jun-Jul;42(6):387-388. doi: 10.1016/j.gastrohep.2018.05.028. Epub 2018 Jul 2.
[Article in English, Spanish]
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adalimumab / adverse effects*
  • Adalimumab / therapeutic use
  • Adrenal Cortex Hormones / adverse effects*
  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Anti-Inflammatory Agents / adverse effects*
  • Anti-Inflammatory Agents / therapeutic use
  • Antifungal Agents / therapeutic use
  • Cilastatin / therapeutic use
  • Crohn Disease / complications
  • Crohn Disease / drug therapy*
  • Diagnosis, Differential
  • Disease Susceptibility
  • Humans
  • Imipenem / therapeutic use
  • Immunocompromised Host
  • Immunosuppressive Agents / adverse effects*
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Opportunistic Infections / diagnosis
  • Opportunistic Infections / drug therapy
  • Opportunistic Infections / etiology*
  • Pulmonary Aspergillosis / diagnosis
  • Pulmonary Aspergillosis / drug therapy
  • Pulmonary Aspergillosis / etiology*
  • Tomography, X-Ray Computed
  • Tuberculosis, Pulmonary / diagnosis

Substances

  • Adrenal Cortex Hormones
  • Anti-Inflammatory Agents
  • Antifungal Agents
  • Immunosuppressive Agents
  • Cilastatin
  • Imipenem
  • Adalimumab